Professor Mark Lowdell PhD FRCPath FRSB is the Professor of Cell & Tissue Therapy at University College London and Director of the Centre for Cell, Gene & Tissue Therapeutics / Honorary Consultant Immunologist at Royal Free Hospital London. He is a qualified diagnostic immunopathologist as well as holding MHRA Qualified Person status for the release of ATMPs for clinical trials and is the current Vice President (Europe & Middle East) of the International Society for Cell Therapy.
He has over 20 years’ experience in adoptive immunotherapy of cancer and has focussed on the role of the innate immune responses; especially the role of natural killer (NK) cells.
He has been particularly interested in translational research and established the first academic GMP facility in the UK for the production of human cells as medicines in 2001. This GMP facility now produces somatic cell medicines, gene therapies and tissue engineered products. Professor Lowdell led the technology transfer of his own adoptive NK cell therapy product into three commercial CMOs in the US and was the chief scientific officer for the US clinical trial.
His interest in clinical translation of cell and tissue therapies led to him being responsible for the first GMP-compliant stem cell-derived airway transplant produced as an ATMP in the EU and he now holds more than £12m funding to perform formal clinical trials of stem cell derived trachea and larynx as well as the first UK clinical trial of an iPS cell-derived product. His newly refurbished ATMP GMP suite at RFH consists of 10 state-of-the-art manufacturing labs and over 20 staff supporting multiple academic and commercial trials.
Professor Lowdell has held and holds numerous appointments to academic and government advisory boards in the UK and overseas. Recently he was a member of the UK Government Regenerative Medicine Expert Review Group and is a member of the scientific advisory boards, consultant to or founder of many of the key companies involved in ATMP development in the EU and USA including Autolus Ltd, Achilles Therapeutics Ltd, Cell Medica Ltd, InmuneBio Inc, NWBio Therapeutics.